MedTrace Logo

Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction in High Responders

NCT00415766 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2016-01-20

No results posted yet for this study

Summary

The purpose of this study is to compare the clinical outcomes of recombinant human chorionic gonadotrophin (rHCG) and urinary HCG (uHCG) in patients undergoing IVF cycles.

Conditions

Interventions

DRUG

rHCG 250ug

Injection of 250 ug Ovitrelle to trigger final oocyte maturation

DRUG

uHCG 5000 IU

Injection of 5000 IU Pregnyl to trigger final oocyte maturation

DRUG

uHCG 7500 IU

Injection of 7500 IU Pregnyl to trigger final oocyte maturation

Sponsors & Collaborators

  • Eugonia

    lead OTHER

Principal Investigators

  • Tryfon Lainas, PhD · Eugonia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-12-31
Completion
2016-07-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00415766 on ClinicalTrials.gov